John W. Childs - 04 Mar 2025 Form 4 Insider Report for Biohaven Ltd. (BHVN)

Role
Director
Signature
/s/ George Clark, Attorney-in-Fact
Issuer symbol
BHVN
Transactions as of
04 Mar 2025
Net transactions value
+$996,238
Form type
4
Filing time
05 Mar 2025, 07:01:52 UTC
Previous filing
31 Dec 2024
Next filing
07 May 2025
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Purchase $759,648 +25,000 +1.1% $30.39 2,320,571 04 Mar 2025 By John W Childs 2013 Revocable Trust F1
transaction BHVN Common Shares Purchase $104,469 +3,400 +16% $30.73 24,452 04 Mar 2025 By 2007 Charitable Remainder Trust F2
transaction BHVN Common Shares Purchase $104,469 +3,400 +4.6% $30.73 76,570 04 Mar 2025 By 2013 Charitable Remainder Trust F2
transaction BHVN Common Shares Purchase $27,653 +900 +3.7% $30.73 25,291 04 Mar 2025 By 1994 Charitable Remainder Trust F2
holding BHVN Common Shares 4,096,512 04 Mar 2025 By 2021 B-H Charitable Remainder Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.17 - $30.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.54 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.